|
|
|
|
在研适应症- |
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Intravenous ORT247 in Healthy Volunteers
This is a single center, double-blinded, randomized, placebo controlled single ascending dose clinical study, with the primary purpose of evaluating the safety, tolerability, pharmacokinetics (PK), and immunohistochemistry of escalating intravenous doses of ORT247 in healthy volunteers.
100 项与 Orthogonal Neuroscience Inc. 相关的临床结果
0 项与 Orthogonal Neuroscience Inc. 相关的专利(医药)
100 项与 Orthogonal Neuroscience Inc. 相关的药物交易
100 项与 Orthogonal Neuroscience Inc. 相关的转化医学